Medicines & Healthcare products Regulatory Agency

MHRA
Regulating Medicines and Medical Devices

Public Assessment Report

Gliclazide Noumed 80mg Tablets

(Gliclazide)

UK Licence No.: PL 44041/0022

Noumed Life Sciences Limited

Lay Summary
Gliclazide Noumed 80mg Tablets
(Gliclazide)

This is a summary of the Public Assessment Report (PAR) for Gliclazide Noumed 80mg Tablets (PL 44041/0022). It explains how Gliclazide Noumed 80mg Tablets were assessed and their authorisation recommended, as well as the conditions of use. It is not intended to provide practical advice on how to use this product.

This medicinal product will be referred to as Gliclazide Tablets in the remainder of the summary, for ease of reading.

For practical information about using Gliclazide Tablets, patients should read the package leaflet or contact their doctor or pharmacist.

What are Gliclazide Tablets and what are they used for?
This medicine is the same as Gliclazide 80 mg tablets (PL 21880/0070) already authorised. The company that makes Gliclazide 80 mg tablets, Medreich Plc, has agreed that its scientific data can be used as a basis for the grant of an identical licence for Gliclazide Tablets (PL 44041/0022).

Gliclazide tablets are used to keep blood sugar at the correct level in adults with non-insulin dependent diabetes when it is not controlled by diet, physical exercise and weight loss alone.

How do Gliclazide Tablets work?
Gliclazide tablets contain the active substance gliclazide which is one of a group of medicines called sulfonylureas. This medicinal product helps to lower blood sugar level.

How are Gliclazide Tablets used?
Gliclazide Tablets are taken by mouth. The whole tablet should be taken orally with food, either with breakfast or with the first main meal of the day.

The usual starting dose in adults and elderly is 40 to 80mg (½ or 1 tablet) daily, adjusted according to the response, up to a maximum of 320mg (four tablets) daily. Up to 160mg (two tablets) can be taken at one time.

The starting dose in the elderly or patients with liver or kidney problems will be reduced.

If a combination therapy of Gliclazide with metformin, an alpha glucosidase inhibitor, a thiazolidinedione, a dipeptidyl peptidase-4 inhibitor, a GLP-1 receptor agonist or insulin is initiated the patient's doctor will determine the proper dose of each medicine individually for them.

If the patient notices that their blood sugar levels are high although they are taking the medicine as prescribed, the patient should contact their doctor or pharmacist.

Gliclazide tablets are not recommended for use in children.

Gliclazide tablets can be obtained with a prescription.

For further information on how Gliclazide tablets are used, please see the Summary of Product Characteristics or the package leaflet available on the MHRA website.

What benefits of Gliclazide Tablets have been shown in studies?
As Gliclazide tablets (PL 44041/0022) are considered to be identical to the reference product, Gliclazide 80 mg tablets (PL 21880/0070), their benefits and risks are taken as being the same as those for the reference product.

What are the possible side effects from Gliclazide Tablets?
Like all medicines, Gliclazide Tablets can cause side effects, although not everybody gets them.

For the full list of all side effects reported with Gliclazide Tablets, see section 4 of the package leaflet.

For the full list of restrictions, see the package leaflet.

Why are Gliclazide Tablets approved?
No new or unexpected safety concerns arose from this application. It was, therefore, considered that the benefits of Gliclazide Tablets outweigh the risks, and the grant of a Marketing Authorisation was recommended.

What measures are being taken to ensure the safe and effective use of Gliclazide Tablets?
A Risk Management Plan (RMP) has been developed to ensure that Gliclazide Tablets are used as safely as possible. Based on this plan, safety information has been included in the Summary of Product Characteristics and the package leaflet for Gliclazide Tablets, including the appropriate precautions to be followed by healthcare professionals and patients.

Other information about Gliclazide Tablets
A Marketing Authorisation was granted in the UK on 19 October 2016.

For more information about taking Gliclazide Tablets, read the package leaflet, or contact your doctor or pharmacist.

The full PAR for Gliclazide Tablets follows this summary.

This summary was last updated in December 2016.

Table of Contents

I Introduction

The Medicines and Healthcare products Regulatory Agency (MHRA) granted Noumed Life Sciences Limited a Marketing Authorisation for the medicinal product Gliclazide Noumed 80mg Tablets (PL 44041/0022) on 19 October 2016. This product is a prescription only medicine (POM), indicated for non-insulin dependent diabetes (type 2) in adults when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose.

This application was submitted as an abridged simple application, according to Article 10c of Directive 2001/83/EC, as amended. The applicant has cross-referred to Gliclazide 80 mg tablets, which was first authorised to Medreich PLC (PL 21880/0070) on 03 December 2010.

Gliclazide is a hypoglycaemic sulphonylurea diabetic active substance differing from other related compounds by an N-containing heterocyclic ring with an endocyclic bond.g. Gliclazide reduces blood glucose levels by stimulating insulin secretion from the beta cellsof the islets of Langerhans. Increase in postprandial insulin and C-peptide secretion persists after two years of treatment.In addition to these metabolic properties, gliclazide has haemovascular properties.

No new data were submitted nor were they necessary for this simple application, as the data are identical to those of the previously granted cross-reference product.

A Risk Management Plan (RMP) and a summary of the pharmacovigilance system have been provided with this application, and these are satisfactory.

The MHRA has been assured that acceptable standards of Good Manufacturing Practice (GMP) are in place for these product types at all sites responsible for the manufacture and assembly of this product.

No new or unexpected safety concerns arose during the review of information provided by the Marketing Authorisation Holder and it was, therefore, judged that the benefits of taking Gliclazide Noumed 80mg Tablets outweigh the risks and a Marketing Authorisation was granted.

II Quality aspects

II.1 Introduction

This is a simple (informed consent) application for Gliclazide Noumed 80mg Tablets (PL 44041/0022), submitted under Article 10c of Directive 2001/83/EC, as amended. The applicant has cross-referred to Gliclazide 80 mg tablets, which was first authorised to Medreich PLC (PL 21880/0070) on 03 December 2010. The current application is considered valid.

II.2. Drug Substance

Drug substance specification

The proposed drug substance specification is consistent with the details registered for the cross-reference product.

II.3. Medicinal Product

Name

The proposed product name is Gliclazide Noumed 80mg Tablets. The product has been named in line with current requirements.

Strength, pharmaceutical form, route of administration, container and pack size

Each tablet contains 80mg Gliclazide, as active ingredient. The route of administration is oral.

The finished product is packed either in:

1. Polyvinylchloride (PVC)/aluminium (Al) blisters or high density polyethylene (HDPE) tablet container with low density polyethylene (LDPE) cap. The pack sizes are 7, 10, 14, 20, 30, 50 or 90 film-coated tablets.

Or

2. Polyvinylchloride (PVC) white opaque/aluminium foil blister packs. Boxes of 28 tablets or 60 tablets are available.

Boxes of 28 tablets contain 2 blister packs each of 14 tablets. Boxes of 60 tablets contain 6 blister packs each of 10 tablets or 3 blister packs each of 20 tablets or 4 blister packs each of 15 tablets.

The proposed shelf-life is 36 months with storage condition “Do not store above 25°C”.

The proposed packaging, shelf-life and storage condition are consistent with the details registered for the cross-reference product.

Marketing Authorisation Holder/Contact Persons/Company

Noumed Life Sciences Limited, 1st Floor, Cattle Market,Hexham, Northumberland, NE46 1NJ

The Qualified Person (QP) responsible for pharmacovigilance is stated and a satisfactory *Curriculum Vitae* (CV) has been provided.

Manufacturers
The proposed manufacturing sites are consistent with those registered for the cross-reference product and evidence of Good Manufacturing Practice (GMP) compliance has been provided.

Qualitative and quantitative composition
The proposed composition is consistent with the details registered for the cross-reference product.

Manufacturing process
The proposed manufacturing process is consistent with the details registered for the cross-reference product and the maximum batch size is stated.

Finished product/shelf-life specifications
The proposed finished product specification is in line with the details registered for the cross-reference product.

Bioequivalence
No bioequivalence data are required to support this simple abridged application as the proposed product is manufactured to the same formula utilising the same process as the cross-reference product, Gliclazide 80 mg tablets (PL 21880/0070).

Expert Report
The applicant cross-refers to the data for Gliclazide 80 mg tablets (PL 21880/0070), to which this application is claimed to be identical. This is acceptable. The applicant has included expert reports of the application. Signed declarations and copies of the experts' CVs are enclosed for the quality, non-clinical and clinical experts. All are considered to have sufficient experience for their responsibilities.

II.4 Discussion on chemical, pharmaceutical and biological aspects
The quality data for this application is consistent with those approved for Gliclazide 80 mg tablets (PL 21880/0070) and, as such, have been judged to be satisfactory. The grant of a Marketing Authorisation is recommended.

III Non-clinical aspects
As this is an abridged simple application submitted under Article 10c of Directive 2001/83/EC, as amended, no new non-clinical data has been supplied and none are required.

A suitable justification has been provided for not submitting an environmental risk assessment.

The grant of a Marketing Authorisation is recommended.

IV Clinical aspects
As this is an abridged simple application submitted under Article 10c of Directive 2001/83/EC, as amended, no new clinical data have been supplied and none are required.

The Marketing Authorisation Holder has provided details of a suitable pharmacovigilance system that fulfils the requirements and provides adequate evidence that they have the services of a qualified person responsible for pharmacovigilance, and have the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country.

Risk Management Plan (RMP)
The applicant has submitted a RMP, in accordance with the requirements of Directive 2001/83/EC as amended, describing the pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to Gliclazide 80 mg tablets.

A summary of safety concerns and planned risk minimisation activities, as approved in the RMP, is listed below:

Safety Concern	**Routine Risk Minimization Measures**	**Additional Risk Minimization Measures**
Important Identified Risks		
Hypoglycaemia	The risk of Hypoglycaemia associated with the use of the drug product is	None

	described in the SmPC sections 4.4, 4.8 and 4.9 and PL sections 2 and 4 and appropriate advice is provided to the prescriber to minimise this risk.	
Hypersensitivity	The risk of hypersensitivity associated with the use of the drug product is described in the SmPC section 4.3 and PL section 2 and appropriate advice is provided to the prescriber to minimise this risk.	None
Juvenile onset diabetes (Type 1 diabetes)	The risk of Juvenile onset diabetes (Type 1 diabetes) associated with the use of the drug product is described in the SmPC sections 4.2 and 4.3 and PL section 2 and 3 and appropriate advice is provided to the prescriber to minimise this risk.	None
Diabetic pre-coma and coma, diabetic keto-acidosis	The risk of Diabetic pre-coma and coma, diabetic keto-acidosis associated with the use of the drug product is described in the SmPC section 4.3 and PL section 2 and appropriate advice is provided to the prescriber to minimise this risk.	None
Pregnancy	The risk associated with the use of drug product during pregnancy is described in the SmPC section 4.3 and PL sections 2 and appropriate advice is provided to the prescriber to minimise this risk.	None
Severe renal or hepatic insufficiency	The risk associated with the use of drug product in severe renal or hepatic insufficiency is described in the SmPC sections 4.3, 4.4 and 4.8 and PL section 2, 4 and appropriate advice is provided to the prescriber to minimise this risk.	None
Poor of blood glucose control	The risk of loss of blood glucose control associated with the use of drug product is described in the SmPC section 4.4 and PL section 2 and appropriate advice is provided to the prescriber to minimise this risk.	None
Increase risk of hypoglycaemia by concomitant use of gliclazide with phenylbutazone, salicylates, sulphonamides, coumarin derivatives, MAOIs, beta adrenergic blocking agents, tetracycline compounds,	The Increase risk of hypoglycaemia by concomitant use of gliclazide with phenylbutazone, salicylates, sulphonamides, coumarin derivatives, MAOIs, beta adrenergic blocking agents, tetracycline compounds, chloramphenicol, clofibrate, disopyramide, miconazole (oral forms) and cimetidine is described in the	None

chloramphenicol, clofibrate, disopyramide, miconazole (oral forms) and cimetidine	SmPC section 4.5 and PL section 2 and appropriate advice is provided to the prescriber to minimise this risk.	
Increase in blood glucose levels by concomitant use of gliclazide with corticosteroids, oral contraceptives, thiazide diuretics, phenothiazine derivatives, thyroid hormones and abuse of laxatives	The risk of Increase in blood glucose levels by concomitant use of gliclazide with corticosteroids, oral contraceptives, thiazide diuretics, phenothiazine derivatives, thyroid hormones and abuse of laxatives is described in the SmPC section 4.5 and PL section 2 and appropriate advice is provided to the prescriber to minimise this risk.	None
Important Identified Risks		
Skin reactions including rash, pruritis, erythmea, bullous eruption, Blood dyscarsia including anaemia, leucopenia, thrombocytopenia and granulocytopenia	The risk of skin reactions including rash, pruritis, erythmea, bullous eruption, Blood dyscarsia including anaemia, leucopenia, thrombocytopenia and granulocytopenia is described in the SmPC section 4.8 and PL section 4 and appropriate advice is provided to the prescriber to minimise this risk.	None
Missing information		
Use in lactating women	The risk of use in lactating women is described in the SmPC section 4.6 and PL section 2 and appropriate advice is provided to the prescriber to minimise this risk.	None

The applicant proposes only routine risk minimisation measures, which are detailed in the SmPC. These are considered sufficient. No additional risk minimisation measures are considered necessary.

The grant of a Marketing Authorisation is recommended.

V User consultation

A user consultation with target patient groups on the PIL has been performed on the basis of a bridging report making reference to the leaflet for Gliclazide 80 mg tablets (PL 21880/0070). The bridging report submitted by the applicant is acceptable.

VI Overall conclusion, benefit/risk assessment and recommendation

The quality of the product is acceptable, and no new non-clinical or clinical concerns have been identified. The applicant's product is identical to the reference product. The benefit risk assessment is, therefore, considered to be positive.

Summary of Product Characteristics, Patient Information Leaflet & Labels

In accordance with Directive 2012/84/EU, the current approved UK versions of the SmPCs and PIL for this product are available on the MHRA website.

The currently approved labelling is listed below:


121XXXX-V1
Gliclazide 80 mg Tablets
PL 44041/0022
MA Holder:
NOUMED LIFE SCIENCES
Space for Batch Embossing

Table of content of the PAR update

Steps taken after the initial procedure with an influence on the Public Assessment Report (Type II variations, PSURs, commitment

Date submitted	Application type	Scope	Outcome